8-K: VolitionRx Reports Strong Revenue Growth and Business Progress in Q3 2024

VolitionRx announced a significant increase in revenue and sales of its Nu.Q Vet Cancer Tests, alongside advancements in human clinical programs and strategic partnerships.

Summary

• VolitionRx Limited announced its financial results and business updates for the third quarter of 2024, showing substantial revenue growth.
• The company sold over 110,000 Nu.Q Vet Cancer Tests in the first three quarters of 2024, expanding availability to 17 countries.
• Volition showcased positive data for its Nu.Q NETs test in sepsis management at a major intensive care conference, involving over 3,000 patients.
• The company is actively pursuing licensing deals in the human clinical space and has opened data rooms for potential near-term opportunities.
• Year-to-date revenue reached $1 million, a 96% increase over the prior year, with Q3 revenue at $475,000, up 187% year-over-year.
• Nu.Q Vet revenue increased by 100% year-to-date and 307% in the third quarter compared to the same periods in 2023.
• Cash used in operating activities decreased by 36% year-over-year to $5.4 million in Q3 due to cost reduction measures.
• The company had approximately $5.4 million in cash and cash equivalents as of September 30, 2024.
• Volition secured over $2.2 million in non-dilutive funding from the Walloon Region, Belgium, with more funding expected in Q1 2025.
• The company aims to achieve cash neutrality in 2025, where income matches expenditure on a cash basis.

Sentiment

Score: 8

Explanation: The document presents a very positive outlook with strong revenue growth, successful product sales, and promising clinical data. The company's focus on cost reduction and securing non-dilutive funding further enhances the positive sentiment. The company is making good progress towards its goals.

Positives

• The company has seen a significant increase in revenue, with a 96% year-to-date increase and a 187% increase in Q3 compared to the previous year.
• Sales of the Nu.Q Vet Cancer Test have been strong, with over 110,000 tests sold in the first nine months of 2024.
• The Nu.Q Vet Cancer Test is now available in 17 countries, expanding its market reach.
• Positive data from studies involving over 3,000 sepsis patients suggests the Nu.Q NETs test could be a valuable tool in predicting patient deterioration.
• The company has made progress in securing licensing deals in the human clinical space.
• Cost reduction measures have led to a 36% decrease in cash used in operating activities in Q3 compared to the previous year.
• Volition has secured over $2.2 million in non-dilutive funding, with more expected in Q1 2025.
• The company has strengthened its board with the appointment of experienced individuals in the diagnostic sector.

Negatives

• The company used $5.4 million in cash for operating activities in the third quarter.
• The company had approximately $5.4 million in cash and cash equivalents as of September 30, 2024.

Risks

• The company's future performance is subject to risks and uncertainties, including the success of clinical studies and regulatory approvals.
• There is a risk that the company may not be able to secure licensing and/or distribution agreements with third parties.
• The company faces competition in the diagnostics and disease monitoring market.
• Downturns in domestic and foreign economies could impact the company's performance.
• The company's intended products may become obsolete due to rapid technological change.

Future Outlook

Volition aims to secure its first licensing deal in the human clinical space and achieve cash neutrality in 2025, meaning income matches expenditure on a cash basis. The company anticipates further non-dilutive funding in Q1 2025.

Management Comments

• Cameron Reynolds, President and Group Chief Executive Officer, stated he is delighted with the sales of over 110,000 Nu.Q Vet Cancer Tests in the first nine months of 2024.
• Cameron Reynolds noted the positive data from three large, independent studies involving more than 3,000 sepsis patients demonstrating that Nu.Q NETs could be used to predict patients at greater risk of deteriorating from sepsis.
• Cameron Reynolds mentioned the near term focus is to secure the first licensing deal in the human clinical space and that the team continues to make good progress with key industry players.

Industry Context

This announcement highlights VolitionRx's progress in the rapidly growing epigenetics and liquid biopsy markets. The company's focus on early cancer detection and sepsis management aligns with current trends in healthcare diagnostics. The expansion of the Nu.Q Vet Cancer Test into 17 countries demonstrates a growing global demand for advanced diagnostic solutions.

Comparison to Industry Standards

• Volition's 96% year-to-date revenue growth and 187% Q3 revenue growth significantly outpaces the average growth rate of many established diagnostic companies, which typically see growth in the range of 5-15% annually.
• The 307% increase in Nu.Q Vet revenue in Q3 is exceptional compared to other veterinary diagnostic companies, which often experience more modest growth rates.
• Companies like Exact Sciences (EXAS) and Guardant Health (GH) are leaders in the human liquid biopsy space, and Volition's progress in securing licensing deals positions them to potentially compete in this market.
• The focus on sepsis diagnostics with the Nu.Q NETs test is a unique approach, as many companies focus on cancer diagnostics. This could give Volition a competitive edge in the sepsis market.
• The company's goal to be cash neutral in 2025 is ambitious, as many biotech companies often operate at a loss for several years while developing and commercializing their products. This indicates a strong focus on financial sustainability.

Management Changes

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and positive clinical data favorably.
• Employees may be encouraged by the company's progress and financial stability.
• Customers will benefit from the expanded availability of the Nu.Q Vet Cancer Test.
• Potential partners may be more inclined to engage with Volition due to its advancements in the diagnostic space.
• Creditors may view the company's cost reduction measures and non-dilutive funding as positive indicators of financial health.

Next Steps

• Volition will host a conference call on November 15, 2024, to discuss the financial and operational results.
• The company will continue to advance commercial discussions with significant players in the diagnostic space.
• Volition will focus on securing its first licensing deal in the human clinical space.
• The company will continue to pursue non-dilutive funding opportunities.
• Volition will work towards achieving cash neutrality in 2025.

Key Dates

Keywords

VolitionRx, Nu.Q Vet Cancer Test, Nu.Q NETs, Epigenetics, Sepsis, Cancer, Liquid Biopsy, Diagnostics, Licensing, Revenue, Financial Results